XToll, a recombinant chaperonin 10 as an anti-inflammatory immunomodulator

Current Opinion in Investigational Drugs

Volumn 9, Issue 5, 2008, Pages 523-533

  Van Eden, W ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CHAPERONIN; PLACEBO; RECOMBINANT CHAPERONIN 10 XTOLL;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; BACTERIAL INFECTION; CELLULITIS; CLINICAL TRIAL; CROHN DISEASE; DISEASE EXACERBATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; HOT FLUSH; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INJECTION SITE EXTRAVASATION; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CHAPERONIN 10; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; PSORIASIS; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 43549083036     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. 407762 Heat shock proteins come of age: Primitive functions acquire new roles in an adaptive world. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL Immunity 1998 8 6 657-665
2. 431104 β-Cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): A randomised, double-blind, phase II trial. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR Lancet 2001 358 9295 1749-1753
3. 483202 Drug datasheet: Rebif (interferon β-1a). Serono SA DRUG DATASHEET WEBSITE 2002 August 30
4. 506643 Toyama Chemical and Eisai announce NDA submission to the Ministry of Health, Labour and Welfare: Toyama and Eisai submit iguratimod NDA in Japan. Toyama Chemical Co Ltd PRESS RELEASE 2003 September 24
5. 553409 Drug datasheet: Enbrel (etanercept). Wyeth DRUG DATASHEET WEBSITE 2004 April 30
6. 590646 Drug datasheet: Avonex (interferon β-1a) IM injection. Genzyme Corp DRUG DATASHEET WEBSITE 2005 March 19
7. 617175 CBio pipeline. CBio Ltd COMPANY WORLD WIDE WEB SITE 2005 August 10
8. 617308 Latest news: News letter & general information. CBio Ltd COMPANY WORLD WIDE WEB SITE 2005 August 11
9. 617313 CBio company website. CBio Ltd COMPANY WORLD WIDE WEB SITE 2005 August 11
10. 617538 Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production. Johnson B, Le Thuy T, Dobbin C, Banovic T, Howard C, Flores FdM, Vanags D, Naylor D, Hill G, Suhrbier A J BIOL CHEM 2005 280 6 4037-4047
11. 620113 Interview: CBio's Cpn10 program for autoimmune diseases/inflammation. CBio Ltd COMPANY COMMUNICATION 2005 August 23
12. 632123 Androclus Therapeutics reports completion of a phase 2 clinical trial of AT-001 (DnaJP1) in patients with rheumatoid arthritis. Androclus Therapeutics PRESS RELEASE 2005 November 02
13. 728935 Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: A double-blind randomised trial. Vanags D, Williams B, Johnson B, Hall S, Nash P, Taylor A, Weiss J, Feeney D LANCET 2006 368 9538 855-863
14. 744808 Betaferon approved in Australia for earliest stages of multiple sclerosis. Schering AG PRESS RELEASE 2006 November 23
15. 751301 PDL BioPharma - Pipeline. PDL Biopharma Inc COMPANY WORLD WIDE WEB SITE 2006 November 21
16. 754832 Chaperonin 10 for rheumatoid arthritis - Authors' reply. Vanags D, Williams B, Johnson B, Feeney D LANCET 2006 368 9551 1962
17. 754833 Heat shock protein 10 modulates innate immunity through interaction with multiple toll-like receptor family members. Dobbin C, Gray C, Naylor D, James A, Flores F, Flesch I, Tully N, Johnson B TISSUE ANTIGENS 2005 66 5 433-434
18. 785526 DeveloGen and Andromeda, a newly formed wholly-owned subsidiary of Clal Biotechnology Industries, sign term sheet for asset purchase agreement for the DiaPep277 program. DeveloGen AG PRESS RELEASE 2007 April 18
19. 789766 FDA approves labeling update for ORENCIA (abatacept) to inhibit structural joint damage in adults with moderate to severe rheumatoid arthritis. Bristol-Myers Squibb Co PRESS RELEASE 2007 April 25
20. 794161 ActoGenix. ActoGenix NV INT BIOTECHNOL CONV & EXHIB 2007 May 06-09 Suppl
21. 799085 Cytos Biotechnology reports results from a phase I/IIa study with CYT007-TNFQb for the treatment of psoriasis. Cytos Biotechnology AG PRESS RELEASE 2007 May 24
22. 799187 Chaperonin 10 regulates the innate immune response to tolllike receptor activation. Johnson B, Vanags D, Dobbin C, Triantafilou K, Gray C, Flesch I INFLAM RES 2007 56 Suppl 2 S125
23. 812245 Company website: Viralytics. Viralytics Ltd COMPANY WORLD WIDE WEB SITE 2007 July 11
24. 823798 Financial report for the year ended 30 June 2006. CBio Ltd ANUAL REPORT 2006 September 22
25. 839089 LEO Pharma: R&D: Pipeline 2007. LEO Pharma A/S COMPANY WORLD WIDE WEB SITE 2007 September 12
26. 840990 CBio Ltd: Financial report for the year ended June 30, 2007. CBio Ltd ANUAL REPORT 2007 June 30
27. 841948 CBio company website. CBio Ltd COMPANY WORLD WIDE WEB SITE 2007 October 22
28. 842021 CBio Limited: Financial report for the year ended 30 June 2007. CBio Ltd ANUAL REPORT 2007 June 30
29. 842029 CBio Limited: Financial report for the year ended 20 June 2005. CBio Ltd ANUAL REPORT 2005 June 30
30. 842031 Prospectus CBio Limited ACN 094 730 417. CBio Ltd COMPANY PROSPECTUS 2007 March 16
31. 842039 Completion of phase 2a clinical trial in rheumatoid arthritis. CBio Ltd PRESS RELEASE 2007 May 09
32. 842041 Termination of phase II(a) clinical trial in ulcerative colitis. CBio Ltd PRESS RELEASE 2007 May 30
33. 842043 Completion of phase 2a clinical trial in plaque psoriasis. CBio Ltd PRESS RELEASE 2007 June 21
34. 842045 Completion of phase 2a clinical trial in multiple sclerosis. CBio Ltd PRESS RELEASE 2006 June 21
35. 864712 Half-year financial report: For the half-year ended 31 December 2007. CBio Ltd 2ND QUARTER REPORT 2007 December 31
36. 868738 Abbott's HUMIRA (adalimumab) receives FDA approval for moderate to severe chronic plaque psoriasis. Abbott Laboratories PRESS RELEASE 2008 January 18
37. 887285 Centocor, Inc. and Schering-Plough submit application requesting approval of golimumab in Europe for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Centocor Inc PRESS RELEASE 2008 March 18
38. 889027 Chaperonin 10 for rheumatoid arthritis. Okamoto H LANCET 2006 368 9551 1961
39. 890348 The Hsp70 and Hsp60 chaperone machines. Bukau B, Horwich AL Cel 1998 92 3 351-366
40. 890364 A synthetic 10-kD heat shock protein (Hsp10) from Mycobacterium tuberculosis modulates adjuvant arthritis. Ragno S, Winrow VR, Mascagni P, Lucietto P, Di Pierro F, Morris CJ, Blake DR Clin Exp Immunol 1996 103 3 384-390
41. 891018 Identification of early pregnancy factor as chaperonin 10: Implications for understanding its role. Cavanagh AC Rev Reprod 1996 1 1 28-32
42. 891092 Heat-shock proteins induce T-cell regulation of chronic inflammation. van Eden W, van der Zee R, Prakken B Nat Rev Immunol 2005 5 4 318-330
43. 891102 Monoclonal antibodies to early pregnancy factor perturb tumour cell growth. Quinn KA, Athanasas-Platsis S, Wong TY, Rolfe BE, Cavanagh AC, Morton H Clin Exp Immunol 1990 80 1 100-108
44. 891105 Effect of monoclonal antibodies to early pregnancy factor (EPF) on the in vivo growth of transplantable murine tumours. Quinn KA, Morton H Cancer Immunol Immunother 1992 34 4 265-271
45. 891106 Hsp-10 in ovarian cancer: Expression and suppression of T-cell signaling. Akyol S, Gercel-Taylor C, Reynolds LC, Taylor DD Gynecol Oncol 2006 101 3 481-486
46. 891107 Expression and regulation of toll-like receptor 2 in rheumatoid arthritis synovium. Seibl R, Birchler T, Loeliger S, Hossle JP, Gay RE, Saurenmann T, Michel BA, Seger RA, Gay S, Lauener RP Am J PathoL 2003 162 4 1221-1227
47. 891109 Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signaling. Kyburz D, Rethage J, Seibl R, Lauener R, Gay RE, Carson DA, Gay S Arthritis Rheum 2003 48 3 642-650
48. 891110 Heat shock protein 60 enhances CD4+ CD25+ regulatory T cell function via innate TLR2 signaling. Zanin-Zhorov A, Cahalon L, Tal G, Margalit R, Lider O, Cohen IR J Clin Invest 2006 116 7 2022-2032
49. 891112 Achievement of a synergistic adjuvant effect on arthritis induction by activation of innate immunity and forcing the immune response toward the Th1 phenotype. Hanyecz A, Berlo SE, Szántó S, Broeren CP, Mikecz K, Glant TT Arthritis Rheum 2004 50 5 1665-1676
50. 891115 Increased arthritis susceptibility in cartilage proteoglycan-specific T cell receptor-transgenic mice. Berlo SE, Guichelaar T, Ten Brink CB, van Kooten PJ, Hauet-Broeren F, Ludanyi K, van Eden W, Broeren CP, Glant TT Arthritis Rheum 2006 54 8 2423-2433
51. 891120 The human early pregnancy factor/chaperonin 10 gene family. Summers KM, Murphy RM, Webb GC, Peters GB, Morton H, Cassady AI, Cavanagh AC Biochem Mol Med 1996 58 1 52-58
52. 891121 The murine chaperonin 10 gene family contains an intronless, putative gene for early pregnancy factor, Cpn10-rs1. Fletcher BH, Cassady AI, Summers KM, Cavanagh AC Mamm Genome 2001 12 2 133-140
53. 891122 Early pregnancy factor in liver regeneration after partial hepatectomy in rats: Relationship with chaperonin 10. Quinn KA, Cavanagh AC, Hillyard NC, McKay DA, Morton H Hepatology 1994 20 5 1294-1302
54. 891125 Molecular chaperones: Multiple functions, pathologies, and potential applications. Macario AJ, Conway de Macario E Front Biosci 2007 1 12 2588-2600
55. 891141 Mucosal expression by B7-positive cells of the 60-kilodalton heat-shock protein in inflammatory bowel disease. Peetermans WE, D'Haens GR, Ceuppens JL, Rutgeerts P, Geboes K Gastroenterology 1995 108 1 75-82
56. 891664 Recent understanding of IBD pathogenesis: Implications for future therapies. Kucharzik T, Maaser C, Lugering A, Kagnoff M, Mayer L, Targan S, Domschke W Inflamm Bowel Dis 2006 12 11 1068-1083
57. 891705 Studies of the rosette inhibition test in pregnant mice: Evidence of immunosuppression? Morton H, Hegh V, Clunie GJ PROC R SOC LOND BIOL 1976 193 1113 413-419
58. 891712 Identification of two suppressor factors induced by early pregnancy factor. Rolfe BE, Cavanagh AC, Quinn KA, Morton H Clin Exp Immunol 1988 73 2 219-225
59. 891727 Lasker clinical medical research award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Feldmann M, Maini RN Nat Med 2003 9 10 1245-1250
60. 891733 Anti-TNF therapy: Where have we got to in 2005? Feldmann M, Brennan FM, Foxwell BM, Taylor PC, Williams RO, Maini RN J Autoimmun 2005 25 Suppl 26-28
61. 891738 Updated consensus statement on biological agents, specifically tumour necrosis factor (TNF) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JWJ, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ Ann Rheum Dis 2004 63 Suppl 2 2-12
62. 891741 Chaperonin 10 in the rat oocytes and early embryos: Its expression and activity for early pregnancy factor. Kawamura K, Fukuda J, Itoh H, Ito K, Kodama H, Kumagai J, Kumagai A, Tanaka T Am J Reprod Immunol 2000 44 4 242-248
63. 891743 Synergistic and differential modulation of immune responses by Hsp60 and lipopolysaccharide. Osterloh A, Kalinke U, Weiss S, Fleischer B, Breloer M J Biol Chem 2007 282 7 4669-4680
64. 891754 The heat-shock proteins. Lindquist S, Craig EA ANU REV GENET 1988 22 631-677
65. 891756 Unfolding the role of chaperones and chaperonins in human disease. Slavotinek AM, Biesecker LG TRENDS GENET 2001 17 9 528 535
66. 891759 NMR analysis of a 900K GroEL GroES complex. Fiaux J, Bertelsen EB, Horwich AL, Wüthrich K NATURE 2002 418 6894 207-211
67. 891761 The crystal structure of the asymmetric GroEL-GroES-(ADP)7 chaperonin complex. Xu Z, Horwich AL, Sigler PB NATURE 1997 388 6644 741-750
68. 891770 Infections, heat shock proteins, and atherosclerosis. Xu Q CURR OPIN CARDIOL 2003 18 4 245-252
69. 891771 Self-heat shock protein 60 induces tumour necrosis factor-α in monocyte-derived macrophage: Possible role in chronic inflammatory periodontal disease. Ueki K, Tabeta K, Yoshie H, Yamazaki K CLIN EXP IMMUNOL 2002 127 1 72-77
70. 891773 Therapeutic approaches in multiple sclerosis: Lessons from failed and interrupted treatment trials. Wiendl H, Hohlfeld R BIODRUGS 2002 16 3 183-200
71. 891775 Inflammatory mechanisms: The molecular basis of inflammation and disease. Libby P NUTR REV 2007 65 12 S140-S146
72. 891778 Rheumatoid arthritis. Arthritis Foundation INTERNET SITE 2007 December 31
73. 891784 National Institute of Health: Questions and answers about psoriasis. National Institute of Health INTERNET SITE 2003 May 31
74. 891958 TLR4 as the mammalian endotoxin sensor. Beutler B CURR TOP MICROBIOL IMMUNOL 2002 270 109-120
75. 891959 Different toll-like receptor agonists induce distinct macrophage responses. Jones BW, Means TK, Heldwein KA, Keen MA, Hill PJ, Belisle JT, Fenton MJ J LEUKOCYTE BIOL 2001 69 6 1036-1044
76. 891972 Cytokine function of heat shock proteins. Tsan MF, Gao B AM J PHYSIOL - CELL PHYSIOL 2004 286 4 C739-C744
77. 892126 Treatment of rheumatoid arthritis. Emery P BMJ (CLINICAL RES ED) 2006 332 7534 152-155
78. 892127 Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T N ENGL J MED 2004 350 25 2572-2581
79. 892128 Heat shock proteins in the pathogenesis of inflammatory skin diseases. Ghoreishi M J Med Dent Sci 2000 47 2 143-150
80. 892129 Multiple Sclerosis: Hope through research. National Institute of Neurological Disorders and Stroke INTERNET SITE 2008 April 02
81. 892133 ACTRN12606000040561: The safety and efficacy of Cpn10 in psoriasis. Australian and New Zealand Clinical Trials Registry INTERNET SITE 2006 January 24
82. 892134 ACTRN12606000037505: The safety of Cpn10 in patients with multiple sclerosis. Australian and New Zealand Clinical Trials Registry INTERNET SITE 2006 January 24
83. 892140 Introduction. Newman SP, Fitzpatrick R, Revenson T, Skevington S, Williams G In: UNDERSTANDING RHEUMATOID ARTHRITIS 1st Edition, Newman SP, Fitzpatrick R, Revenson T, Skevington S, Williams G (Eds), Routledge, London, UK 1995 1-6
84. 892143 Clinical features. van de Kerkhof PCM In: TEXTBOOK OF PSORIASIS 2nd Edition, van de Kerkhof PCM (Ed), Blackwell Publishing Inc, Malden, MA, USA 2003 3-29
85. 892144 Multiple sclerosis: Diagnosis and definitions. Feinstein F In: CLIN NEUROPSYCHIATRY MULTIPLE SCLEROSIS 1st Edition, Feinstein F (Ed), Cambridge University Press, Cambridge, UK 2007 1-27
86. 892146 Introduction: Inflammatory bowel diseases: From bench to bedside. Targan S, Shanahan F, Karp LC INFLAMATORY BOWEL DIS FROM BENCH TO BEDSIDE Targan S, Shanahan F, Karp LC (Eds) Springer-Verlag, New York, NY, USA 2005 3-4
87. 892148 Tuberculosis associated with infliximab, a tumor necrosis factor ?-neutralizing agent. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM N ENGL J MED 2001 345 15 1098-1104
88. 892149 Phase 1a and 1b clinical trials of chaperonin 10 in healthy volunteers and patients with multiple sclerosis. Broadley S, Johnson B, Feeney D, Shakib S J Neurol Sci 2005 238 Suppl 1 Abs 0487
89. 892152 A multicentre, phase IIa clinical trial of Cpn10 in multiple sclerosis. Broadley SA, Johnson B, Vanags D, Feeney D, Griffiths L, Shakib S, Snow T, Brown G, Taylor J, Coulthardt A, Kneebone C ECTRIMS 2007 October 11-14 Abs 585
90. 892160 EAE: History, clinical signs, and disease course. Lindsey WJ In: EXPERIMENTAL MODELS OF MULTIPLE SCLEROSIS Lavi E, Constantinescu CS (Eds) Springer, New York, NY, USA 2005 1-9
91. 892199 Cutting edge: Heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. Ohashi K, Burkart V, Flohé S, Kolb H J IMMUNOL 2000 164 2 558-561
92. 892203 For the safe use of steroid therapy. Cautionary side effects of steroid drugs. Hashimoto H JPN J EXP MED 2004 81 5 798-802
93. 892206 Heat shock proteins are targets for T cell regulation: How microbial Hsp induce IL10 producing anti-inflammatory T cells. van Eden W In: HEAT SHOCK PROTEINS: POTENT MEDIATORS OF INFLAMATION AND IMMUNITY Asea AA, de Maio A (Eds) Springer, New York, NY, USA 2007 1 289-308
94. 892231 The use of biological agents in the treatment of rheumatoid arthritis. Fan PT, Leong KH AN ACAD MED SINGAPORE 2007 36 2 128-134
95. 892361 Personal communication: Confirmation of the XToll construct. CBio Ltd COMPANY COMMUNICATION 2008 March 28